ISSN 2692-5877
DOI: *10.46998/IJCMCR.2020.01.000013*

International Journal of
Clinical Studies & Medical Case Reports

Review Article

Assessment of Interference Approaches in Response to COVID-19 Outbreak

Khurshied AK*[1], Junwei L[2], Murtaza H[3], Ikram ul HM[1], Jamal MK[4], Zahoor M[5], Osama G[6], Muhammad HS[7], Hameed MS[1], Khaliq MA[1], Shahbaz A[1], Ahmed KK1, Tahria BQ[1], Maqbool A[1], Nisar H[1], Matlob A[1], Ijaz Hussain M[1] and Asma N[1]

[1]Ghazi University City Campus, Dera Ghazi Khan 32200, Pakistan
[2]Department of Infectious Diseases, The Second Hospital of Nanjing, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, [210003], China. Public Health and Therapy Center of Nanjing, Nanjing, [211113], China
[3]Department of Biochemistry and Biotechnology The Islamia University Bahawalpur 63100, Pakistan.
[4]Cholistan University of Veterinary and Animal Sciences, Pakistan
[5]China Agriculture University Beijing
[6]Nowshera Medical College, (KMU) Nowshera, Pakistan
[7]Iqra University Islamabad Pakistan

***Corresponding author:** Khurshied Ahmed Khan, Ghazi University City Campus, Dera Ghazi Khan 32200, Pakistan. E-mail: kakhan@gudgk.edu.pk

Received: May 18, 2020 Published: June 23, 2020

Abstract

The start of (2020) is underway with the rise of novel coronavirus known as SARS –CoV-2 that triggering pneumonia-related respiratory syndrome all over the world. It is the third intensive pathogenic and contagious coronavirus after severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) appeared in humans. The cause of beginning, diffusion to humans and contrivances linked with the pathogenicity of SARS-CoV-2 are not vibrant yet, however, its similarity with SARS-CoV and numerous other bat coronaviruses was newly established and concluded through genome sequencing interrelated studies. The progress of therapeutic strategies is required in order to inhibit further epidemics and cure disease-ridden people. In this Review, we summarize existing data about the development, source, diversity, and epidemiology of three pathogenic coronaviruses with a detailed attention on the present outburst in Wuhan, China. Additionally, we discuss the clinical features and potential therapeutic possibilities that may be effective counter to SARS CoV-2.

Key words: Novel coronavirus; Outbreak; Therapeutics

Introduction

The episode of coronavirus infection 2019 (COVID-19) gears in Wuhan city, Hubei province of China initially developed in December 2019. Recently known unique coronavirus (SARS-CoV-2, earlier known as 2019-nCoV) is affecting pneumonia related respiratory syndrome [1]. Subsequently investigation of genome classifications of SARS-CoV-2 samples collected from various disease-ridden patients, SARS-CoV-2 bonds strong sequence uniqueness with SARS- CoV [2]. At mid of April 2020, about 209 countries reported >1.9 million cases of SARSCoV-2 infection. Patients diseased with SARS-CoV-2 showed confirmation of common pneumonia with serious lung damage [3]. COVID-19 could be distinguished by clinical CT radiography or a laboratory real time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) [4].

Clinical features connected with patients affected with SARS -CoV, MERS -CoV and SARS - CoV-2 ranging from a slight respirational epidemic to serious critical respiratory illness. Both MERS and SARS patients in later phases mature respiratory suffering and renal letdown. Pneumonia appears to be the record and repeated index of SARS -CoV-2 infection, considered mainly by fever, cough, dyspnea, and related infiltrates on chest imaging. The period from infection to appearance of symptoms differs. Commonly, it is supposed to be 14 days, but, a study group at Guangzhou Medical University stated the maturation period to be 24 days. In a local cluster of groups and joint families the infections start of fever and respiratory illness signs transpired about three to six days after possible contact [11].

Therapeutic Possibilities for Human Coronaviruses

Presently no favorable antiviral cure existing, however, frequent compounds have been established active against SARS -CoV and MERS -CoV but not verified extensively for recently appeared SARS -CoV – 2.

Development of Neutralizing Antibodies to 2019-Ncov

Coronavirus access rises with the S protein binding to a desti-

Copyright © All rights are reserved by Damiano C*[1], Bunino FM[1], Veronesi P[1], Platto M1 and Zuliani W[1]

nation receptor on the cell surface, where after merging is facilitated at the cell membrane, providing the viral nucleocapsid into the cell for consecutive duplication [12]. The S protein is well-known for triggering syncytial development into diseased cells and receptor-containing cells around them, highlighting that the S proteins are not only functional in the virion state.

A neutralizing antibody aiming the S protein on the surface of 2019-nCoV is possibly the first therapy expected by biomedical investigators in academics and industry, serve as an inert protection to illness [13]. The newly available genome sequence of 2019-nCoV (GenBank: MN908947.3) permits scientists to triumph gene fusion in the lab and reflect stating the S protein as an immunogen. Conventional approaches of screening mice or rabbits for neutralizing antibodies may be quite passive for this outbreak, but quick methods such as, super computer that express antibody fragments could be used to classify prime competitor for viral neutralization [14].

The problem is that some antibody aspirant would be carefully deep-rooted in cell culture and animal models to endorse that it can neutralize 2019-nCoV and avert epidemic. Evidence from other coronaviruses types such as SARS could be supportive to target the best epitope in order to create neutralizing antibodies (the receptor-binding area in the S protein is a significant target) [15], but again this is a time consuming and thought-provoking procedure, which might not return substantial advances for some months. Furthermore, finally a combination of antibodies might be vital to safeguard full defense for long suffering patients, which could enhance supplementary complication for preparation and production.

A substitute approach of creating counterbalancing antibodies contrary to 2019-nCoV S protein could develop immunity in large animals (sheep, goat, and cow) with the 2019-nCoV S protein, and then liberating and cleaning the polyclonal antibodies from the animals [16].This approach may assist an accelerated facility in the background of an epidemic and has several leads such as could hypothetically confuse any cure developments [18]. In a really anxious situation, this approach may be practical streamlining assembly and built-up, but has partial assurances that every animal could create neutralizing antisera, or the antibody titer present in each animal [17]. In addition, the human immune reaction's counter to foreign immuno-globulins to other species, which for a precise range, but not balanced in the 2019-nCoV epidemic, that is promptly proliferating currently [19].

Perceptions on the Progress of Neutralizing Antibodies against SARS-Cov-2

To practice the Plasma transfusion of recovered patients in the infected patients would be an alternative approach during the outbreak, due to presence of Polyclonal Nabs. [20]. These Polyclonal NAbs could be active and effective in in handling SARS-CoV-2 if induced properly [21]. Further these NAbs can deal with inactive immune responses to viral infection in the patients. Actually Convalescent plasma therapy was successfully applied to SARS and Ebola infected patients in past and established and marked as curing therapy but the problem and challenges during this therapy are irregularity inert plasma and inconsistency of sera in different patients [23].

To make the therapeutic antibodies successful antibody-antigen computational model can developed to monitor the strategy [24]. The Protein Data Bank (PDB) Statistics shown that about (presently about 2,000 testimonies) of antibody configurations are accessible. Though Assembled data base of these PDB statistics, the comparative specific characteristic of antibody against viral infection can be projected. The significant development and advancement in NAbs can be documented to can make available profile for researcher will be key for the vaccines counter to SARS-CoV-2. The crucial residues of boundary between an antibody and the antigen can be improved to yield in elevation affinity [25]. Numerous current computer cropping models have been used to guess the interface between S protein and human ACE2 [21] or antibodies [26]. The studies Int. J. Biol. Sci. 2020, Vol. 16 http://www.ijbs.com 1722 exposed the significant finding that SARS-CoV specific CR3022 antibody could cross-react to SARSCoV-2.

Via Oligonucleotides against 2019-Ncov RNA Genome

In addition to targeting the extracellular proteins of 2019-nCoV, the RNA genome itself can be targeted to be dispersed. The recently identified published 2019-nCoV genome sequence (GenBank: MN908947.3) could be consider another strategy Then, is it the use of small interfering RNA (siRNA) or antisense oligonucleotides (ASO) to fight the virus targeting its RNA genome [27]. The first problem with this strategy is unknown sequence of RNA domain of Cov-2109 Isolating preserved classifications is crucial before in direction to adjust siRNA leveling and reduce viral outflow of the oligonucleotide strategy. The comparative genome homology study of 2019-nCov will be significant to identify conserved sequence. The delivery of oligonucleotides into the lungs would be second big challenge for this purpose lipid nanoparticles can be effective delivery vehicle to the lungs [28]. It is still unclear how much siRNA's or ASO's delivered within the lungs would be effective to stop the infection. For example, if lungs had siRNA or ASO 25% of alveolar epithelial cells that competence strength be a pronounced achievement over for traditional gene therapy, but would scarcely mark any metamorphosis in a epidemiologic infection [29]. Such siRNA candidates description correspondingly expose in case of failed Ebola trials, while its preclinical success in animal models [30]. Finally, if someone supposed that siRNA was result oriented clinically, but to to a large infected population there is inadequate capacity of SiRNA in manufacturing drug. Existing siRNA and ASO treatments are manufactured for rare diseases, and there are no available resources existing to manufacture the medications quickly [31].

Chemotherapeutic Alternatives for SARS-Cov-2 Infection

To handle the infected patients there is no prescribed clinical drug or vaccine developed or yet permitted by authorities Precautionary and life supporting treatments are presently deliver to infected patients .These prescription and set of established therapies include , antibiotic treatment along with oxygen therapy and further and antifungal treatment, extra-corporeal membrane oxygenation (ECMO) etc. according to symptoms of patients [31]. The seven antiviral drugs on Vero E6 cells in vitro were evaluated by Wang et al against SARS-CoV-2 infection, chloroquine, remdesivir (GS-5734), favipiravir (T-750), penciclovir, nitazoxanide, nafamostat, ribavirin, nitazoxanide, nafamostat [32]. The anti-malaria drug chloroquine and remdesivir were found more effective with low cytotocity as compared other seven drug treatments. The concentration (EC50) for chloroquine and remdesivir were 0.77μM and 1.13μM respectively which showed better improvements in the patients. Chloroquine is found effective in Vero E6 cells at different stages of SARS-CoV-2 infection (viral entry and post-entry

stages) whereas s at post –entry stage remdesivir is more effective.

The antiviral activities of Chloroquine as a drug used for a malarial infection with potential broad-spectrum are established in the past [33]. The previous successful clinical trial indicates that with EC90 (6.90 μM) in Vero E6 cells is clinically achievable against SARS-Cov with significant results [27]. While Remdesivir as a drug presently under consideration which was effective during SARS-CoV and MERS-CoV in the past [34]. Remdesivir improves the functioning adenosine analogue and targeting RdRp, which results in in early expiry of the virus transcription. The most suitable trial of EC90 in Vero E6 cells is 1.76 μM with remdesivir against SARS-CoV-2 in nonhuman primate experiment is achievable [34]. In the United States, it is encouraging to note that treatment with remdesivir against viral infection was recommended to the patient on the day 7 without any adversarial events witnessed. The patient's clinical symptoms improved on day 8 and the earlier condition wiped out, indicating the remdesivir capacity be effective to the treatment of SARS-CoV-2 infection. However this result should be taken with attention and care as this is only single case study and a proper trial control was lacking [34]. Presently, chloroquine and remdesivir are under phase 3 clinical trial and open-label trial for treatment of SARS-CoV-2 infection respectively. Initial results displayed that chloroquine phosphate had deceptive efficiency in handling of COVID-19. However, consideration required be taken during clinical practice of chloroquine as its overdose is exceptionally terrible without known solution [34].

Conclusion

SARS-CoV-2 is an developing threat and evolving infection, lacking actual treatment and existing drug or vaccine for instant management. The current mortality rate 2.3% of SARS-CoV-2 which is extremely alarming due to large number of infected patients could result in failure of health system of many states within short period of time ,and its strong apprehension that mortality rate might increase with of passage of time if defensive measures not taken in time

In addition, finical assistance is required to research groups to prepare antiviral drug within short span of time. In the meantime, to avoid the epidemic of this and other novel viruses in future.

Guideline should be vigorously adopted by states to forbid the trade of uninhabited animals in food staff, because they are conceivable intermediary host(s) of several viruses. During the unexpected existing outbreak to deal with patients, Nabs therapeutic option remains at high significance .In coming couple of months Nabs therapeutic approach and its understanding mechanism may offer potential proposal for speedy progress of antibody therapy and vaccine for SARS-Cov-2.

References

1.Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;38:727-33.

2.Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74.

3.Jiang S, Xia S, Ying T, Lu L. A novel coronavirus (2019-nCoV) causing pneumonia- associated respiratory syndrome. Cell Mol Immunol. 2020. doi: 10.1038/s41423-020-0372-4. [Epub ahead of print].

4.Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology. 2020. doi: 10.1148/radiol.2020200343. [Epub ahead of print].

5.Li G, Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery. 2020. doi: 10.1038/d41573-020-00016-0. [Epub ahead of print].

6.Klasse PJ. Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Adv Biol. 2014;2014:157895.

7.Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res.2019;105:93-116. 10.1016/bs.aivir.2019.08.002.

8.Casadevall A, Pirofski LA. The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases. PLoS Pathog. 2015;11(4):e1004717. 10.1371/journal.ppat.1004717.

9.Shin YW, Chang KH, Hong GW, et al. Selection of Vaccinia Virus-Neutralizing Antibody from a Phage-Display Human-Antibody Library. J Microbiol Biotechnol.2019;29(4):651–657. 10.4014/jmb.1812.12024.

10.Keck ZY, Wang Y, Lau P, et al. Isolation of HCV Neutralizing Antibodies by Yeast Display. Methods Mol Biol. 2019;1911:395-419. 10.1007/978-1-4939-8976-8_27.

11.Elshabrawy HA, Coughlin MM, Baker SC, et al. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One. 2012;7(11):e50366. 10.1371/journal.pone.0050366.

12.Tripathi NK, Shrivastava A: Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development. Front Bioeng Biotechnol.2019;7:420. 10.3389/fbioe.2019.00420.

13.Schmidt R, Beltzig LC, Sawatsky B, et al. Generation of therapeutic antisera for emerging viral infections. NPJ Vaccines. 2018;3:42-10. 10.1038/s41541-018-0082-4.

14.Jahrling PB, Geisbert J, Swearengen JR, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.Arch Virol Suppl. 1996;11:135-140. 10.1007/978-3-7091-7482-1_12.

15.Goto M, Kuribayashi K, Umemori Y, et al. High prevalence of human anti-mouse antibodies in the serum of colorectal cancer patients. Anticancer Res. 2010;30(10):4353-4356.

16.Thi EP, Mire CE, Lee AC, et al.: Lipid nanoparticle siRNA treatment of Ebola-virus- Makona-infected nonhuman primates. Nature. 2015;521(7552):362–365. 10.1038/nature14442.

17.Thi EP, Lee AC, Geisbert JB, et al. Rescue of non-human primates from advancedSudan ebolavirus infection with lipid encapsulated siRNA. Nat Microbiol. 2016;1(10): 16142. 10.1038/nmicrobiol.2016.142.

18.Tsai CH, Lee PY, Stollar V, et al. Antiviral therapy targeting viral polymerase. Curr Pharm Des. 2006;12(11):1339-1355. 10.2174/138161206776361156.

19.Anderson J, Schiffer C, Lee SK, et al. Viral protease inhibitors. Handb Exp Pharmacol. 2009;189:85-110. 10.1007/978-3-540-79086-0_4.

20.Litterman N, Lipinski C, Ekins S: Small molecules with antiviral activity against the Ebola virus [version 1; peer review: 2 approved]. F1000Res. 2015;4:38. 10.12688/f1000research.6120.1.

21.Dodd LE, Follmann D, Proschan M, et al. A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. Sci Transl Med. 2019;11(520): pii: eaaw1049. 10.1126/scitranslmed.aaw1049
22.Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256. 10.1136/thorax.2003.012658.
23.Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.Nat Commun. 2020;11(1): 222. 10.1038/s41467-019-13940-6
24.Li CC, Wang XJ, Wang HR. Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discov Today. 2019;24(3):726–736. 10.1016/j.drudis.2019.01.018.
25.Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885–4893. 10.1128/AAC.03036-14.
26.Mire CE, Geisbert JB, Agans KN, et al. Passive Immunotherapy: Assessment of Convalescent Serum against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis. 2016;214(suppl 3):S367–S374. 10.1093/infdis/jiw333.
27.Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016;14(2):152–157. 10.2450/2015.0131-15.
28.Kraft CS, Hewlett AL, Koepsell S, et al. The Use of TKM-100802 and Convalescent Plasma in 2 Patients with Ebola Virus Disease in the United States. Clin Infect Dis. 2015;61(4):496-502. 10.1093/cid/civ334.
29.Walker LM, Burton DR. Passive immunotherapy of viral infections: 'super-antibodies' enter the fray. Nat Rev Immunol. 2018;18(5):297-308. 10.1038/nri.2017.148.
30.PREVAIL II Writing Group, Multi-National PREVAIL II Study Team, Davey RT, Jr, et al. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016;375(15):1448-1456. 10.1056/NEJMoa1604330.
31.Zhou P, Yang XL, Wang XG, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv.2020; 2020.01.22.914952. 10.1101/2020.01.22.914952.
32.Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13.
33.Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020. [Epub ahead of print].
34.Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020. [Epub ahead of print].